RecruitingPHASE1, PHASE2NCT04421820

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bold Therapeutics, Inc.
Intervention: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)(drug)
Enrollment: 220 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2026

Study locations (18)

University of California, Los Angeles, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Cross Cancer Institue, Edmonton, Alberta, Canada
Juravinski Cancer Centre, Hamilton, Ontario, Canada
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
McGill University Health Centre Glen Site, Montreal, Quebec, Canada
Universitatsklinikum Bonn, Bonn, Germany
University Hospital of Ulm, Ulm, Germany
Mater Miserecordiae University Hospital, Dublin, Ireland
St. James Hospital, Dublin, Ireland
St. Vincent's University Hospital, Dublin, Ireland
National Cancer Center, Goyang, South Korea
Kangbuk Samsung Hospital, Seoul, South Korea
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04421820 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials